Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK crawled time : 09:00 save search
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: 0.2%
vaccine dengue tak-003 qdenga
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
Published: 2024-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -1.98%
fy2023 management momentum growth
Takeda Announces Chief Financial Officer Succession
Published: 2024-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -1.98%
financial
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
Published: 2023-09-29 (Crawled : 09:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.51%
H: 0.42%
C: -0.26%
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: 0.59%
H: 0.82%
C: -0.65%
drug japan application submission
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
Published: 2023-05-11 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -1.83%
H: 0.12%
C: -3.06%
fy2022 growth
Plasma Protein Therapeutics Market to Reach $44,296.78 million, Globally, by 2031 at 5.2% CAGR: Allied Market Research
Published: 2023-04-12 (Crawled : 09:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.91%
H: 0.36%
C: -0.42%
BAX | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.8%
C: -0.97%
GRFS | News | $6.53 -0.76% -0.77% 760K
|
Health Technology
|
| O: 4.55%
H: 0.0%
C: -4.35%
ADMA 4 | $6.21 2.82% 2.74% 3M
|
Health Technology
|
| O: 3.1%
H: 0.0%
C: -6.31%
research protein therapeutics market
Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients
Published: 2022-11-02 (Crawled : 09:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.15%
H: 0.72%
C: -0.98%
diagnostic technology platform
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 22, 2022
Published: 2022-06-22 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.28%
H: 0.0%
C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 1.36%
H: 0.0%
C: 0.0%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: -0.64%
H: 14.95%
C: 10.14%
nasdaq grant therapeutics employment compensation
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
Published: 2022-06-09 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.18%
H: 0.66%
C: -0.88%
vaccine trial qdengue
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
Published: 2022-05-31 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -2.24%
H: 0.35%
C: -0.14%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 5.09%
H: 0.0%
C: 0.0%
covid-19 japan vaccine authorization
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Published: 2022-05-31 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -2.24%
H: 0.35%
C: -0.14%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 5.09%
H: 0.0%
C: 0.0%
covid-19 japan vaccine authorization
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
Published: 2022-05-11 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -1.25%
H: 0.35%
C: -2.38%
fy2021 fy2022 expected growth
Takeda Announces Completion of Acquisition of Own Shares - Apr 13, 2022
Published: 2022-04-13 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.2%
H: 1.83%
C: 1.83%
acquisition
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting - Apr 01, 2022
Published: 2022-04-01 (Crawled : 09:00) - biospace.com/
MNTS | $0.371 -4.63% -4.85% 130K
|
|
| O: -0.31%
H: 3.14%
C: -0.94%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.56%
H: 0.76%
C: 0.76%
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
Published: 2021-10-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 2.03%
H: 3.33%
C: 0.07%
brands results growth liver
Takeda Announces Acquisition of Own Shares - Oct 28, 2021
Published: 2021-10-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 2.03%
H: 3.33%
C: 0.07%
acquisition
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 21, 2021
Published: 2021-10-21 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.28%
H: 0.07%
C: -0.57%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.32%
H: 0.05%
C: -0.55%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: -0.23%
H: 3.07%
C: 1.97%
granted grant
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
Published: 2021-09-30 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.74%
H: 0.73%
C: -0.3%
therapy collaboration syndros commercialization
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
Published: 2021-09-16 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.41%
H: 1.11%
C: 0.76%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.23%
H: 0.31%
C: -1.02%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.0%
H: 0.83%
C: 0.34%
renal cell carcinoma
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
Published: 2021-07-30 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
results topline growth liver positive
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.